Changes in the mouse estrus cycle in response to Brca1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer (Cancer Research (2010) 70, (221-8) DOI: 10.1158/0008-5472.CAN-09-3232;Changes in the mouse estrus cycle in response to Brca1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer

Cancer Research

Volumn 70, Issue 1, 2010, Pages 221-228

  Hong, Hao ^a   Yen, Hai Yun ^a   Brockmeyer, Amy ^a   Liu, Ying ^a   Chodankar, Rajas ^a   Pike, Malcolm C ^a   Stanczyk, Frank Z ^a   Maxson, Robert ^a   Dubeau, Louis ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; GONADOTROPIN; PROGESTERONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CIRCULATION; CONTROLLED STUDY; ENDOMETRIUM CELL; EPITHELIUM TUMOR; ESTRUS CYCLE; FEMALE; FOLLICULAR PHASE; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GONADOTROPIN BLOOD LEVEL; GRANULOSA CELL; MOUSE; MUTANT; NONHUMAN; ONCOGENE; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROESTRUS; RISK FACTOR; SPORADIC OVARIAN CANCER; STIMULATION; WILD TYPE;

EID: 75149193110     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0036     Document Type: Erratum

References (30)

1. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 2004;83:186-95.
2. Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136: 1184-203.
3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
4. Ford D, Easton DF, Stratton M, et al. Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62:676-89.
5. King MC, Marks JH, Mandell JB, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
6. Risch HA, MaLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68:700-10.
7. Chiang JW, Karlan BY, Cass L, Baldwin RL. BRCA1 methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 2006;101: 403-10.
8. Wang C, Horluchi A, Imai T, et al. Expression of BRCA1 protein in benign, borderline, and malignant ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004;202:215-23.
9. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a casecontrol study. Lancet Oncol 2007;8:26-34.
10. Narod SA, Risch HA, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998;339:424-8.
11. Chodankar R, Kwang S, Sangiorgi F, et al. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional brca1 in ovarian granulosa cells. Curr Biol 2005;15: 561-5.
12. Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ. Limitations of direct estradiol and testosterone immunoassay kits. Steroids 2003;68:1173-8.
13. Schedin P, Mitrenga T, Kaeck M. Estrous cycle regulation of mammary epithelial cell proliferation, differentiation, and death in the Sprague-Dawley rat: a model for investigating the role of estrous cycling in mammary carcinogenesis. J Mammary Gland Biol Neoplasia 2000;5:211-25.
14. Smith MS, Freeman ME, Neill JD. The control of progesterone secretion during the estrous cycle and early pseudopregnancy in the rat: prolactin, gonadotropin and steroid levels associated with rescue of the corpus luteum of pseudopregnancy. Endocrinology 1975;96: 219-26.
15. Walmer DK, Wrona MA, Hughes CL, Nelson KG. Lactoferrin expression in the mouse reproductive tract during the natural estrous cycle: correlation with circulating estradiol and progesterone. Endocrinology 1992;131:1458-66.
16. Wood GA, Fata JE, Watson KLM, Khokha R. Circulating hormones and estrous stage predict cellular and stromal remodeling in murine uterus. Reproduction 2007;133:1035-44.
17. Griswold MD, Heckert L, Linder C. The molecular biology of the FSH receptor. J Steroid Biochem Mol Biol 1995;53:215-8.
18. Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding progestin. Cancer 2009;115:531-9.
19. Purdie DM, Bain CJ. Ovulation and risk of epithelial cancer. Int J Cancer 2003;104:228-32.
20. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf) 1998;49:695-707.
21. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 1996;63:254-7.
22. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-5.
23. Zhou H, Luo MP, Schonthal AH, et al. Effect of reproductive hormones on ovarian epithelial tumors. I. Effect on cell cycle activity. Cancer Biol Ther 2002;1:300-6.
24. Hu Y, Ghosh S, Amleh A, et al. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 2005;24:8343-8.
25. Levran D, Ben-Shlomo I, Luski A, Ben-Rafael JD, Mashiach S, Seidman D. A reappraisal of the feedback effects of oestradiol upon luteinizing hormone surge. Hum Reprod 1995;10:3117-20.
26. Ordog T, Goldsmith JR, Chen M-D, Connaughton A, Hotchkiss J, Knobil E. On the mechanism of the positive feedback action of estradiol on luteinizing hormone secretion in the rhesus monkey. J Clin Endocrinol Metab 1995;83:4047-53.
27. Fowler PA, Templeton A. The nature and function of putative gonadotrophin-surge attenuating/inhibiting factor (GnSAF/IF). Endocr Rev 1996;17:103-20.
28. Messinis IE. Ovarian feedback, mechanism of action and possible clinical implications. Hum Reprod 2006;12:557-71.
29. Fowler PA, Sorsa T, Harris WJ, Knight PG, Mason HD. Relationship between follicle size and gonadotrophin surge factor (GnSAF) bioactivity during spontaneous cycles in women. Hum Reprod 2001;16: 1353-8.
30. Fowler PA, Sorsa-Leslie T, Cash P, et al. A 60-66 kDa protein with gonadotrophin surge attenuating factor bioactivity is produced by human ovarian granulosa cells. Mol Hum Reprod 2002;8: 823-32.